These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 16639430

  • 21. Advocating for rectal microbicides.
    AIDS Read; 2008 May; 18(5):235. PubMed ID: 18589876
    [No Abstract] [Full Text] [Related]

  • 22. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J, Coplan P, Wainberg MA.
    Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
    [Abstract] [Full Text] [Related]

  • 23. Current and future microbicide approaches aimed at preventing HIV infection in women.
    Pozzetto B, Delézay O, Brunon-Gagneux A, Hamzeh-Cognasse H, Lucht F, Bourlet T.
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):167-83. PubMed ID: 22339191
    [Abstract] [Full Text] [Related]

  • 24. Microbicides may be ready.
    AIDS Patient Care STDS; 2002 May; 16(5):243. PubMed ID: 12055033
    [No Abstract] [Full Text] [Related]

  • 25. Should microbicides be controlled by women or by physicians?
    Piret J, Bergeron MG.
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e14-7. PubMed ID: 20932483
    [Abstract] [Full Text] [Related]

  • 26. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
    Mallipeddi R, Rohan LC.
    Expert Opin Drug Deliv; 2010 Jan; 7(1):37-48. PubMed ID: 20017659
    [Abstract] [Full Text] [Related]

  • 27. Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission.
    Vacas Córdoba E, Arnaiz E, Relloso M, Sánchez-Torres C, García F, Pérez-Álvarez L, Gómez R, de la Mata FJ, Pion M, Muñoz-Fernández MÁ.
    AIDS; 2013 May 15; 27(8):1219-29. PubMed ID: 23925376
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.
    Hladik F, Doncel GF.
    Antiviral Res; 2010 Dec 15; 88 Suppl 1(Suppl 1):S3-9. PubMed ID: 21109065
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Current State of Microbicide Development.
    Traore YL, Chen Y, Ho EA.
    Clin Pharmacol Ther; 2018 Dec 15; 104(6):1074-1081. PubMed ID: 30107032
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
    Buckheit KW, Furlan-Freguia C, Ham AS, Buckheit RW.
    Curr Top Med Chem; 2016 Dec 15; 16(10):1118-34. PubMed ID: 26324047
    [Abstract] [Full Text] [Related]

  • 37. Rectal microbicides in development.
    Willyard C.
    Nat Med; 2009 Aug 15; 15(8):829. PubMed ID: 19661974
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
    Roberts L, Liebenberg L, Barnabas S, Passmore JA.
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug 15; 26(4):441-9. PubMed ID: 22429786
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.